Search Results - "Johnston, R. D."

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer by Pegram, Mark, Jackisch, Christian, Johnston, Stephen R. D.

“…The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13–22% of breast cancers (BC). Approximately 60–70% of HER2+ BC co-express hormone…”
Get full text

Microstructural and mechanical insight into atherosclerotic plaques: an ex vivo DTI study to better assess plaque vulnerability by Tornifoglio, B., Johnston, R. D., Stone, A. J., Kerskens, C., Lally, C.

“…Non-invasive microstructural characterisation has the potential to determine the stability, or lack thereof, of atherosclerotic plaques and ultimately aid in…”
Get full text

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways by Johnston, Stephen R D

“…Overcoming primary or secondary endocrine resistance in breast cancer remains critical to further enhancing the benefit of existing therapies such as tamoxifen…”
Get full text

Phosphotungstic acid (PTA) preferentially binds to collagen- rich regions of porcine carotid arteries and human atherosclerotic plaques observed using contrast enhanced micro-computed tomography (CE-µCT) by Hanly, A, Johnston, R D, Lemass, C, Jose, A, Tornifoglio, B, Lally, C

“…Atherosclerotic plaque rupture in the carotid artery can cause small emboli to travel to cerebral arteries, causing blockages and preventing blood flow leading…”
Get full text

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update by Burstein, Harold J, Somerfield, Mark R, Barton, Debra L, Dorris, Ali, Fallowfield, Lesley J, Jain, Dharamvir, Johnston, Stephen R D, Korde, Larissa A, Litton, Jennifer K, Macrae, Erin R, Peterson, Lindsay L, Vikas, Praveen, Yung, Rachel L, Rugo, Hope S

“…To update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. An Expert Panel conducted a…”
Get full text

Avascular midline oropharyngeal anatomy allows for expanded indications for transoral robotic surgery in pediatric patients by Johnston, D. R., Maurrasse, S. E., Maddalozzo, J. M.

“…Transoral robotic surgery (TORS) in children is in its infancy, and indications have been primarily limited to lingual tonsillar hypertrophy and superficial…”
Get full text

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer by Cristofanilli, Massimo, Johnston, Stephen R. D., Manikhas, Alexey, Gomez, Henry L., Gladkov, Oleg, Shao, Zhimin, Safina, Sufia, Blackwell, Kimberly L., Alvarez, Ricardo H., Rubin, Stephen D., Ranganathan, Sulabha, Redhu, Suman, Trudeau, Maureen E.

“…This multi-center Phase II study evaluated lapatinib, pazopanib, and the combination in patients with relapsed HER2+ inflammatory breast cancer. In Cohort 1,…”
Get full text

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer by Johnston, Stephen R. D., Gómez, Henry, Stemmer, Salomon M., Richie, Maria, Durante, Michael, Pandite, Lini, Goodman, Vicki, Slamon, Dennis

“…This phase II study (VEG20007; NCT00347919) with randomized and open-label components evaluated first-line lapatinib plus pazopanib therapy and/or lapatinib…”
Get full text

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer by Paluch-Shimon, Shani, Neven, Patrick, Huober, Jens, Cicin, Irfan, Goetz, Matthew P., Shimizu, Chikako, Huang, Chiun-Sheng, Lueck, Hans Joachim, Beith, Jane, Tokunaga, Eriko, Contreras, Jessica Reyes, de Sant’Ana, Rosane Oliveira, Wei, Ran, Shahir, Ashwin, Nabinger, Sarah C., Forrester, Tammy, Johnston, Stephen R. D., Harbeck, Nadia

“…Background: Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+),…”
Get full text

Regional anthropometric measures associated with the severity of liver injury in patients with non‐alcoholic fatty liver disease by Subramanian, V., Johnston, R. D., Kaye, P., Aithal, G. P.

“…Summary Background Not all NAFLD patients are obese and many obese patients do not have NAFLD. Impaired peripheral fat storage may increase the delivery of…”
Get full text

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study by Goetz, Matthew P., Cicin, Irfan, Testa, Laura, Tolaney, Sara M., Huober, Jens, Guarneri, Valentina, Johnston, Stephen R. D., Martin, Miguel, Rastogi, Priya, Harbeck, Nadia, Shahir, Ashwin, Wei, Ran, André, Valérie, Rugo, Hope S., O’Shaughnessy, Joyce

“…In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit…”
Get full text

New Strategies in Estrogen Receptor―Positive Breast Cancer by JOHNSTON, Stephen R. D

“…Endocrine therapy has led to a significant improvement in outcomes for women with estrogen receptor-positive (ER+) breast cancer. Current questions in the…”
Get full text

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer by Garcia-Murillas, Isaac, Chopra, Neha, Comino-Méndez, Iñaki, Beaney, Matthew, Tovey, Holly, Cutts, Rosalind J, Swift, Claire, Kriplani, Divya, Afentakis, Maria, Hrebien, Sarah, Walsh-Crestani, Giselle, Barry, Peter, Johnston, Stephen R D, Ring, Alistair, Bliss, Judith, Russell, Simon, Evans, Abigail, Skene, Anthony, Wheatley, Duncan, Dowsett, Mitch, Smith, Ian E, Turner, Nicholas C

“…Current treatment cures most cases of early-stage, primary breast cancer. However, better techniques are required to identify which patients are at risk of…”
Get more information

Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer by Angelis, Vasileios, Johnston, Stephen R D, Ardestani, Amin, Maedler, Kathrin

“…A critical decline of functional insulin-producing pancreatic β-cells is the central pathologic element of both type 1 and type 2 diabetes. Mammalian Sterile…”
Get full text

Endoscopic evaluation of the gastro-duodenal tolerance of short-term analgesic treatment with 25 mg diclofenac-K liquid capsules by Hawkey, C., Burnett, I., Gold, M. S., Garsed, K., Stevenson, D., Mannath, J., Norman, A., Shepherd, V., Subramanian, V., Johnston, R. D., Brown, M.

“…Summary Background Diclofenac‐potassium (diclofenac‐‐K) 25 mg liquid capsule is absorbed more quickly than the tablet formulation. It offers potential for…”
Get full text

Are we missing the mTOR target in breast cancer? by Johnston, Stephen R. D.

Get full text

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments by Omarini, Claudia, Thanopoulou, Eirini, Johnston, Stephen R. D.

“…To review the available published data regarding the incidence, mechanisms of pathogenesis, clinical presentations and management of pneumonitis caused by…”
Get full text

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer by Roylance, Rebecca, Endesfelder, David, Jamal-Hanjani, Mariam, Burrell, Rebecca A., Gorman, Patricia, Sander, Jil, Murphy, Niamh, Birkbak, Nicolai Juul, Hanby, Andrew M., Speirs, Valerie, Johnston, Stephen R. D., Kschischo, Maik, Swanton, Charles

“…Regulators of transition through mitosis such as SURVIVIN and Aurora kinase A (AURKA) have been previously implicated in the initiation of chromosomal…”
Get full text

A review on the added value of whole-body MRI in metastatic lobular breast cancer by Bhaludin, Basrull N., Tunariu, Nina, Koh, Dow-Mu, Messiou, Christina, Okines, Alicia F., McGrath, Sophie E., Ring, Alistair E., Parton, Marina M., Sharma, Bhupinder, Gagliardi, Tanja, Allen, Steven D., Pope, Romney, Johnston, Stephen R. D., Downey, Kate

“…Invasive lobular breast carcinomas (ILC) account for approximately 15% of breast cancer diagnoses. They can be difficult to diagnose both clinically and…”
Get full text

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy by Johnston, Stephen R. D., Semiglazov, Vladimir F., Manikhas, George M., Spaeth, Dominique, Romieu, Gilles, Dodwell, David J., Wardley, Andrew M., Neven, Patrick, Bessems, Annick, Park, Youn C., De Porre, Peter M., Perez Ruixo, Juan J., Howes, Angela J.

“…Background This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast…”
Get full text